Mr. Michal Efraty reports

NEUROTHERA LABS INC. CLOSES FIRST TRANCHE OF NON-BROKERED PRIVATE PLACEMENT

Neurothera Labs Inc. has closed the first tranche of its non-brokered private placement, as previously announced on June 30, 2026, and July 2, 2026.

Under the first tranche, the company raised $2.7-million (Canadian) from the sale of 22.5 million units at 12 Canadian cents per unit. Each unit comprises one common share in the capital of the company and one common share purchase warrant. Each unit warrant entitles the holder to purchase one common share for 11.5 U.S. cents per common share, equivalent to 16 Canadian cents per common share, until Aug. 12, 2029. The unit warrants will also have an acceleration provision whereby upon the securities of Neurothera being approved for trading on the Nasdaq Stock Market, the company will accelerate the expiry date of 50 per cent of the unexercised unit warrants and provide three business days of advance written notice to holders thereof of such accelerated expiry date. The unit warrants are non-transferable.

The company intends to use the net proceeds of the first tranche for general working capital purposes, including the evaluation of prospective transactions, settlement of liabilities, including repayment of outstanding indebtedness owed to SciSparc Ltd., and other corporate and administrative expenses. All securities issued in connection with the first tranche, including any common shares and common shares issuable upon exercise of unit warrants, are subject to a restricted period of four months and one day from the date hereof. The offering is subject to the final approval of the TSX Venture Exchange and any other applicable regulatory approvals.

In connection with the first tranche, the company paid an aggregate finder's fee of $222,750 (Canadian) to a qualified arm's-length party. The finder was also issued 2,812,500 common shares as compensation to the finder.

About Neurothera Labs Inc.

Neurothera Labs is a clinical-stage pharmaceutical company focused on developing novel therapeutics for central nervous system disorders and other underserved health conditions through collaborations and innovative combinations.

We seek Safe Harbor.